Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × inavolisib × Clear all

Phase

Status

Recruiting 8 Not yet recruiting 2 Withdrawn 1 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Cyclophosphamide 627 Cisplatin 587 Gemcitabine 555 Bevacizumab 535 Carboplatin 524 Paclitaxel 517 Docetaxel 497 Radiotherapy 482 Fluorouracil 361 Oxaliplatin 342 Rituximab 326 Capecitabine 311 Doxorubicin 308 Etoposide 285 Filgrastim 282 Irinotecan 276 Dexamethasone 270 Leucovorin 249 Cetuximab 229 pembrolizumab 224 Cytarabine 204 Bortezomib 197 Trastuzumab 192 Erlotinib Hydrochloride 189 Vincristine 187 Prednisone 187 Nivolumab 185 Pemetrexed 176 fludarabine phosphate 169 Temozolomide 168

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

German Cancer Research Center

Phase 2 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡